Catalent has completed clinical production of Bridge Therapeutics Inc.’s opioid addiction therapeutic product, BT-219, and executed an Exclusive Licensing Agreement to use Catalent’s Zydis orally disintegrating tablet (ODT) technology. Bridge intends to seek approval from the U.S. FDA for BT-219 under the 505(b)(2) regulatory submission pathway as well as a possible future single entity buprenorphine product. Catalent’s Zydis ODT technology is a unique, freeze-dried tablet that disperses almo...